FY2029 EPS Estimates for enGene Decreased by Leerink Partnrs

enGene Holdings Inc. (NASDAQ:ENGN) – Equities researchers at Leerink Partnrs reduced their FY2029 earnings per share estimates for enGene in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn $0.57 per share for the year, down from their previous forecast of $0.60. The consensus estimate for enGene’s current full-year earnings is ($1.57) per share.

enGene (NASDAQ:ENGN) last announced its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06.

Several other research analysts also recently weighed in on ENGN. Citizens Jmp upgraded enGene to a “strong-buy” rating in a report on Monday, November 18th. Raymond James initiated coverage on enGene in a research note on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price objective on shares of enGene in a research note on Monday, December 23rd. Finally, HC Wainwright initiated coverage on shares of enGene in a research report on Monday, December 23rd. They issued a “buy” rating and a $25.00 target price on the stock. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $29.78.

enGene Trading Up 1.2 %

Shares of NASDAQ:ENGN traded up $0.09 during trading on Thursday, reaching $7.04. The stock had a trading volume of 2,455 shares, compared to its average volume of 91,959. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The business has a fifty day moving average price of $7.39 and a 200-day moving average price of $7.54. The stock has a market cap of $311.09 million, a P/E ratio of -12.13 and a beta of -0.65. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08.

Institutional Trading of enGene

Large investors have recently bought and sold shares of the company. Wolverine Asset Management LLC bought a new stake in shares of enGene in the third quarter worth $37,000. Point72 Asset Management L.P. boosted its stake in enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after acquiring an additional 619,100 shares during the period. Finally, Franklin Resources Inc. grew its holdings in shares of enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after purchasing an additional 389,918 shares during the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.